Nyxoah Appoints Liam Kelly as New CEO
Nyxoah (NASDAQ: NYXH) has announced that Liam Kelly will become its new chief executive officer, effective October 1, 2026. He succeeds Olivier Taelman and is expected to lead the company during a strategic shift toward becoming more U.S.-focused following recent FDA approval of Genio and its launch in the United States. Kelly's appointment reflects Nyxoah’s broader commercial strategy as it scales operations post-launch, leveraging his experience to drive growth. The leadership transition underscores confidence in the company’s long-term vision for market expansion and product adoption within a key regulatory environment. The change is not expected to have an immediate impact on financial performance but signals strategic alignment with U.S.-centric commercial goals.
Tickers: $NYXH
Topics: executive appointment FDA approval leadership change